References 1. Eljaaly K, Alshehri S, Mahoney MV. Antibiotic dosing discrepancies in the 2014 skin and soft tissue guidelines. Clin Infect Dis 2015; 60:1731–2. 2. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 Update by the infectious diseases society of America. Clin Infect Dis 2014; 59: 47–159. Correspondence: Dennis L. Stevens, PhD, MD, VA Medical Center, Infectious Disease Section, 500 West Fort St, Bldg 117, Boise, ID 83702 ([email protected]).
Reply to Eljaaly et al TO THE EDITOR—This response is written on behalf of the members of the Infectious Diseases Society of America (IDSA) Skin and Soft Tissue Guidelines Committee. Thank you for your thoughtful response [1] to the IDSA Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections 2014 [2]. We agree that in Table 3 the dose of ciprofloxacin could be either 500 mg PO every 12 hours or a range of 500 to 750 mg PO every 12 hours. We also agree that from Table 4 the recommended dose for treatment of Aeromonas hydrophila necrotizing infection should be 400 mg IV every 12 hours and that the dose of ceftriaxone for treatment of Vibrio vulnificus should be 1 gram IV every day (qd) and not qid. An erratum has been issued correcting Table 4 in Clinical Infectious Diseases.
Note Potential conflict of interest. Author certifies no potential conflicts of interest. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Dennis L. Stevens Chairman Infectious Diseases Society of America Guidelines for the Treatment and Management of Skin and Soft Tissue Infections Committee
1732
•
CID 2015:60 (1 June)
•
CORRESPONDENCE
Downloaded from http://cid.oxfordjournals.org/ at University of Connecticut on May 15, 2015
Clinical Infectious Diseases® 2015;60(11):1732 © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals. [email protected]. DOI: 10.1093/cid/civ127
Reply to Eljaaly et al TO THE EDITOR—This response is written on behalf of the members of the Infectious Diseases Society of America (IDSA) Skin and Soft Tissue Guidelines Committee. Thank you for your thoughtful response [1] to the IDSA Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections 2014 [2]. We agree that in Table 3 the dose of ciprofloxacin could be either 500 mg PO every 12 hours or a range of 500 to 750 mg PO every 12 hours. We also agree that from Table 4 the recommended dose for treatment of Aeromonas hydrophila necrotizing infection should be 400 mg IV every 12 hours and that the dose of ceftriaxone for treatment of Vibrio vulnificus should be 1 gram IV every day (qd) and not qid. An erratum has been issued correcting Table 4 in Clinical Infectious Diseases.
Note Potential conflict of interest. Author certifies no potential conflicts of interest. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Dennis L. Stevens Chairman Infectious Diseases Society of America Guidelines for the Treatment and Management of Skin and Soft Tissue Infections Committee
1732
•
CID 2015:60 (1 June)
•
CORRESPONDENCE
Downloaded from http://cid.oxfordjournals.org/ at University of Connecticut on May 15, 2015
Clinical Infectious Diseases® 2015;60(11):1732 © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals. [email protected]. DOI: 10.1093/cid/civ127
